FDA CDER Impact Story: Advancing Chemical Modeling to Assess Mutagenic Risks - Drug Information Update

https://www.fda.gov/drugs/regulatory-science-action/impact-story-cder-assessment-drug-impurity-mutagenicity-quantitative-structure-activity-relationship?utm_campaign=FDA%20CDER%20Impact%20Story%3A%20Advancing%20Chemical%20Modeling%20to%20Assess%20Mutagenic%20Risks&utm_medium=email&utm_source=Eloqua

FDA CDER Impact Story: Advancing Chemical Modeling to Assess Mutagenic Risks

When drug developers are selecting candidate structures to investigate as future therapies, they can use (Q)SAR models to predict the relative toxicity of potential drug products before any lab testing is performed. This enables rapid decisions to be made on which candidates might be most safely developed.

Learn More